|
|
|
|
|
|
|
|
|
|
"The phase II clinical trial evaluated responses in 44 ovarian cancer patients in their first relapse period, who received either farletuzumab as a single agent or in combination with carboplatin and a taxane..."cont'd
Thursday, June 10, 2010
ASCO: (Farletuzumab) Antibody Shows Promise in Ovarian Cancer
"The phase II clinical trial evaluated responses in 44 ovarian cancer patients in their first relapse period, who received either farletuzumab as a single agent or in combination with carboplatin and a taxane..."cont'd
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.